Elixi, Author at Elixi International - Page 3 of 13

16 January 2023

Fabio Macchi is our new Head of Medical and Quality Departments.

0 Comments1 Minute

30 March 2022

Carvykti (ciltacabtagene autoleucel), new gene therapy to treat adult patients with multiple myeloma

0 Comments3 Minutes

11 March 2022

Jardiance (empagliflozin)approved for Wider Range of Patients with Heart Failure

0 Comments3 Minutes

9 March 2022

Kimmtrak (tebentafusp), a monotherapy for the treatment of adult patients with uveal melanoma, a rare type of eye cancer.

0 Comments3 Minutes

7 February 2022

Breyanzi (lisocabtagene maraleucel) New gene therapy treatment for patients with relapsed or refractory large B-cell lymphoma

0 Comments4 Minutes

3 November 2021

Cyltezo(adalimumab-adbm), the First Interchangeable Biosimilar to Humira

0 Comments3 Minutes

25 October 2021

Trodelvy (sacituzumab govitecan), First-in-class medicine to treat aggressive form of breast cancer

0 Comments3 Minutes

21 September 2021

Byooviz (ranibizumab-nuna), First Biosimilar to Treat Macular Degeneration Disease and Other Eye Conditions

0 Comments3 Minutes

18 June 2021

Astepro (azelastine hydrochloride nasal spray, 0.15%), nasal antihistamine approved for nonprescription use

0 Comments2 Minutes

8 June 2021

Aduhelm (aducanumab), first new Alzheimer’s drug in 20 years.

0 Comments5 Minutes